Navigation Links
ofatumumab in Medical News

Genmab Initiates Ofatumumab Phase II Study in Diffuse Large B-Cell Lymphoma

Summary: Genmab has Initiated a Phase II Study of Ofatumumab in Relapsed Diffuse Large B-Cell Lymphoma COPENHAGEN, Denmark, December 13 /PRNewswire-FirstCall/ -- Genmab A/S (OMX: GEN) announced today that study centers have been initiated and are ready to enroll patients in...

Genmab and GlaxoSmithKline Initiate Ofatumumab Rheumatoid Arthritis Phase III Program

Summary: Genmab and GSK Have Announced the Initiation of the Phase III Program With Ofatumumab to Treat Rheumatoid Arthritis. COPENHAGEN, Denmark, November 20 /PRNewswire-FirstCall/ -- Genmab A/S (OMX: GEN) and GlaxoSmithKline (LSE and NYSE: GSK) announced today the initiation of the ...

GlaxoSmithKline and Genmab Submit Arzerra(TM) (Ofatumumab) Application to FDA for the Treatment of Advanced Stage Blood Cancer

...t (refractory) to previous therapies. If approved, ofatumumab would be the first anti-CD20 monoclonal antibody a...se effects.(4) "The submission of the BLA for ofatumumab brings us closer to the possibility of providing a... in these patient groups treated with single-agent ofatumumab was 58 percent for the fludarabine alemtuzumab ref...

GlaxoSmithKline's Drug Will Become New Clinical Gold Standard by 2012 for the Treatment of Relapsed/Refractory CLL

...ision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that GlaxoSmithKline's ofatumumab will become Decision Resources' proprietary clinical gold-standard treatment for relapsed/refractory chronic lymphocytic leukemia (CLL) by 2012. This ...

Genmab Announces 2008 First Half Year Results

...follows: We achieved a development milestone for ofatumumab (HuMax-CD20(R)) under the collaboration with Glaxo...evaluate a subcutaneous route of administration of ofatumumab (HuMax-CD20(R)) in rheumatoid arthritis (RA). We... results from a Phase III pivotal study evaluating ofatumumab (HuMax-CD20(R)) in two groups of patients with chr...

The Monoclonal Antibodies Drug Market for the Treatment of Cancer Will More Than Double to $16.7 Billion By 2016

...onstrained environment limits off-label use. Market sales will also be driven by the introduction of four new MAbs by 2016: Genmab/GlaxoSmithKline's ofatumumab for non-Hodgkin's lymphoma and chronic lymphocytic leukemia, Medarex/Bristol-Myers Squibb's ipilimumab for malignant myeloma, Genmab's zanolimumab for...

GlaxoSmithKline Presents Innovative Neuroscience Pipeline

...arketed therapies -- Phase II program for use of ofatumumab in multiple sclerosis announced, with trials i...r more effective and more convenient treatments. ofatumumab (HuMax-CD20), a promising monoclonal antibody, wil...ine Seretide TORCH Volibris (EU) ofatumumab (RA) (EU) Tykerb (US) Requip XL (PD) (U...
ofatumumab in Medical Technology

Recruitment Completed in Ofatumumab NHL Pivotal Study

Summary: Genmab has Completed Recruitment of Patients in the Phase III Study of Ofatumumab in Rituximab Refractory Follicular NHL COPENHAGEN, September 23 /PRNewswire-FirstCall/ -- Genmab A/S (OMX: GEN) announced today it has completed recruitment of patients in the pivotal Phase III st...

Genmab Announces Upcoming Ofatumumab Studies

Front Line CLL, NHL and CLL Retreatment and Japanese Development Studies Planned COPENHAGEN, Denmark, August 25 /PRNewswire-FirstCall/ -- Genmab has announced plans to begin four studies of ofatumumab in chronic lymphocytic leukemia and non-Hodgkin's lymphoma. ...

Genmab and GlaxoSmithKline Announce Positive Top-Line Results in Ofatumumab Chronic Lymphocytic Leukemia Pivotal Study

Summary: Phase III Pivotal Study of Ofatumumab in Refractory CLL Meets Primary Endpoint COPENHAGEN, July 31 /PRNewswire-FirstCall/ -- Genmab A/S (OMX: GEN) and GlaxoSmithKline (LSE and NYSE: GSK) announced today positive top-line results from an interim analysis of ...

Genmab A/S - Company Announcement: Recruitment Completed In Ofatumumab CLL Front Line Study

COPENHAGEN, Denmark, July 9 /PRNewswire-FirstCall/ -- Summary: Genmab has completed recruitment of patients in the Phase II study of ofatumumab in combination with fludarabine and cyclophosphamide to treat front line CLL. Genmab A/S (OMX: GEN) announced today it has completed recruitment of ...

Genmab Reaches Milestone in Ofatumumab Collaboration

Summary: Genmab has Reached a Milestone in its Ofatumumab Collaboration With GlaxoSmithKline COPENHAGEN, June 30 /PRNewswire-FirstCall/ -- Genmab A/S (OMX: GEN) announced today it has reached a development milestone for ofatumumab (HuMax-CD20(R)) under the terms of its...

Genmab A/S - Company Announcement Ofatumumab in Subcutaneous Study in Rheumatoid Arthritis Summary: Subcutaneous Administration of Ofatumumab Investigated in Phase I/II Study

COPENHAGEN, Denmark, June 10 /PRNewswire-FirstCall/ -- Genmab A/S (OMX: GEN) announced today a Phase I/II study to evaluate a subcutaneous route of administration of ofatumumab (HuMax-CD20(R)) in rheumatoid arthritis (RA) patients, stable on methotrexate will be initiated soon. The study, whic...

FDA Advisory Panel Makes Favorable Recommendation for GlaxoSmithKline and Genmab's ARZERRA(TM) (ofatumumab)

...ease is refractory to fludarabine and alemtuzumab. ofatumumab is an investigational treatment. "The committee's positive vote in support of ofatumumab is a potential milestone for patients with CLL. Wh...ies. "The positive vote by ODAC confirms that ofatumumab may offer a new treatment option for patients who ...

Arzerra(TM) (ofatumumab) Demonstrates High Response Rates in Patients With Fludarabine Refractory Chronic Lymphocytic Leukemia (CLL)

... Data from a pivotal trial suggests that ofatumumab has activity in heavily pre-treated patients who h...ia (CLL). The results demonstrate the potential of ofatumumab for heavily pre-treated patients with CLL who do n...merican Society of Hematology, 6-9 December, 2008. ofatumumab is an investigational drug that has not been appro...

Genmab Announces Updates on Phase III Cancer Studies

...nterim analysis (N=132 patients) in the pivotal Phase III clinical trial of ofatumumab (HuMax-CD20(R)) in refractory chronic lymphocytic leukemia (CLL) has now re...cation in this indication is expected to be filed before the end of 2008. ofatumumab is an investigational drug being developed to treat CLL, follicular non-Hod...

GlaxoSmithKline and Genmab Present Positive Phase II Results With ofatumumab in Patients With Rheumatoid Arthritis (RA)

...(abstract number: OPO232) from a Phase II study of ofatumumab (HuMax-CD20(R)) in patients with rheumatoid arthritis (RA). ofatumumab is being co-developed under a worldwide agreement ...f four treatment groups (300 mg, 700 mg or 1000 mg ofatumumab or placebo) and assessed based on their of Rheumat...
ofatumumab in Biological Technology

Genmab A/S: Ofatumumab Pivotal CLL Data to be Presented at ASH

Responses Significantly Correlated to Overall Survival Summary: Three ofatumumab Abstracts Have Been Accepted for Presentation at the ASH Meeting December 6-9, 2008 COPENHAGEN, November 10 /PRNewswire-FirstCall/ -- Genmab A/S (OMX: GEN) announced today that three of...

Genmab Reaches Milestone in Ofatumumab Collaboration

Summary: Genmab has Reached the Sixth Milestone in its Ofatumumab Collaboration With GSK. COPENHAGEN, Denmark, October 10 /PRNewswire-FirstCall/ -- Genmab A/S (OMX: GEN) announced today it has reached the sixth milestone for ofatumumab (HuMax-CD20(R)) under the terms ...

Genmab Reaches Fifth Milestone in Ofatumumab Collaboration

Summary: Genmab Will Receive a Milestone Payment of Approximately DKK 232.7 Million From GSK for Achievement of Positive Results in the Phase III CLL Study COPENHAGEN, August 21 /PRNewswire-FirstCall/ -- Genmab A/S (OMX: GEN) announced today it has reached the fi...

Genmab Reaches Milestones in Ofatumumab Collaboration

Summary: Genmab has Achieved Two Development Milestones in its Ofatumumab Collaboration With GlaxoSmithKline. COPENHAGEN, January 21 /PRNewswire-FirstCall/ -- Genmab A/S (OMX: GEN) announced today it has reached the second and third development milestones for ofatumumab (HuMax-...

Genmab Announces Details of Planned Ofatumumab Phase II Study in Multiple Sclerosis

Summary: Genmab has Announced Details of a Planned Phase II Study of Ofatumumab to Treat Relapsing Remitting Multiple Sclerosis COPENHAGEN, Denmark, December 13 /PRNewswire-FirstCall/ -- Genmab A/S (OMX: GEN) announced today details of a planned Phase II study of ofatumumab (HuMax-CD20...

Genmab Announces Update on Recruitment of Patients in ofatumumab CLL Pivotal Study

Summary: Genmab and GlaxoSmithKline Have Completed Recruitment of 66 CLL Patients Respectively to Both Study Groups in a Pivotal Study of ofatumumab COPENHAGEN, Denmark, November 28 /PRNewswire-FirstCall/ -- Genmab A/S (OMX: GEN) announced today recruitment of 132 patients has been completed i...

Genmab Amends Ofatumumab Pivotal Study in NHL to Single Arm Study

Summary: Genmab has Amended the Design of the Ofatumumab Pivotal Study in Rituximab Refractory Follicular Non-Hodgkin's lymphoma and Reduced the Number of Patients to Approximately 81 COPENHAGEN, September 27 /PRNewswire-FirstCall/ -- Genmab A/S (OMX: GEN) announced today it ...

Genmab Announces Encouraging Preclinical Data for ofatumumab

Summary: Genmab Announces ofatumumab Appeared More Effective Than rituximab in a Pre-Clinical Study COPENHAGEN, Denmark, September 7 /PRNewswire-FirstCall/ -- Genmab A/S (OMX: GEN) announced today that ofatumumab (HuMax-CD20(R)) appeared more effective at inducing compleme...

Genmab Announces Results for the First Nine Months of 2008

... results from a Phase III pivotal study evaluating ofatumumab (HuMax-CD20(R)) in two groups of patients with chr...nt. We completed recruitment in a second pivotal ofatumumab study in refractory non-Hodgkin's Lymphoma (NHL) p... We announced plans to begin four studies with ofatumumab this year: 1) Phase III CLL front line chlorambu...

Genmab Announces Year End 2007 Financial Results

...xpenses. Of the research and development costs, we expect to spend approximately DKK 500 million (approximately USD 98 million) on development for the ofatumumab program. Total projected revenues for 2008 are expected to be approximately DKK 1.0 billion (approximately USD 197 million), an increase of approxim...
Other Tags
(Date:1/22/2015)... 22, 2015 The City of West Hollywood hosted ... to commemorate the 42nd anniversary of the Supreme Court decision Roe ... been 42 years since the Roe vs. Wade decision and the ... present as ever,” said City of West Hollywood Councilmember Abbe Land. ...
(Date:1/22/2015)... 2015 VogueQueen is a seasoned and trusted ... many designers are thrilled to have it lead the wedding ... new collection of prom dresses for the global market. , ... strategic vision and he focuses on continuing the goal of ...
(Date:1/22/2015)... January 23, 2015 AngelWeddingDress, the premier ... 2015 maternity wedding dresses. View website of ... looking for maternity wedding dresses online for a bridal ... with high quality for them. Its maternity wedding dresses ...
(Date:1/22/2015)... 22, 2015 Thousand of GranuFlo lawsuits ... recalled its GranuFlo and NaturaLyte dialysis concentrates continue to ... U.S. District Court, District of Massachusetts, Bernstein Liebhard LLP ... Court has remanded a case filed by the state ...
(Date:1/22/2015)... Joan Lunden, award-winning American journalist, beloved television host, ... 32nd Annual Miami Breast Cancer Conference planned and ... , shares that “a fast-growing, virulent” cancer in her ... not followed up her clean mammogram with an ultrasound. ...
Breaking Medicine News(10 mins):Health News:VogueQueen Unveils New Designs of Prom Dresses for 2015 2Health News:AngelWeddingDress Has Recently Released Its Collection Of 2015 Maternity Wedding Dresses 2Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 2Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 3Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 4Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 2Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 3Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 4Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 5Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 6
(Date:12/19/2014)... 2014  23andMe, Inc., the leading personal genetics company, today announced ... genetic ancestry of individuals from across the United ... than four hundred years ago, the United States ... from different continents. This study illuminates how American history and ...
(Date:12/17/2014)... Dec. 16, 2014 Valencell, a leader in performance ... technology to industry leaders such as Intel, Jabra, Atlas, ... biometric wearable products. These products will be showcased at ... Las Vegas . "Our partners ...
(Date:12/11/2014)... , Dec. 09, 2014 Research and Markets ... ( http://www.researchandmarkets.com/research/9ql3kr/biometrics_market ) has announced the addition of the ... their offering. One major trend emerging ... systems. Multimodal biometric systems utilize more than one characteristic ...
Breaking Biology News(10 mins):23andMe Study Sketches Genetic Portrait of the United States 223andMe Study Sketches Genetic Portrait of the United States 323andMe Study Sketches Genetic Portrait of the United States 4Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2Biometrics Market in India 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2
Other Contents